News | Mammography | July 10, 2019

SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis

ProFound AI solution for DBT offers high-performing workflow solution for radiologists

SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis

July 10, 2019 — Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-cleared artificial intelligence (AI) program for significantly enhancing early breast cancer detection for 3-D mammography. The AI program, called ProFound AI for digital breast tomosynthesis (DBT), is a technology developed by iCAD Inc.

ProFound AI for DBT is a high-performance, deep learning, workflow solution that assists radiologists reading mammography. It is the first and only FDA-cleared 3-D tomosynthesis technology using artificial intelligence, according to the company.

“Implementing ProFound AI into our processes for breast cancer screenings will improve detection of breast cancer and reduction of false positives and recalls,” said John Simon, M.D., founder and CEO of SimonMed. “With the enhanced technology available through 3-D mammography, the review of the 84 slices of breast tissue per breast will now be expedited, but does not replace the specialized radiologist.”

SimonMed Imaging is one of the largest outpatient medical imaging providers and largest physician radiology practices in the United States. 

ProFound AI for DBT was FDA-cleared in 2018 and offers benefits to both radiologists and patients alike. Designed to detect malignant soft-tissue densities and calcifications, the software provides radiologists with key data, such as Certainty of Findings and Case Scores, which can assist radiologists in making clinical decisions and prioritizing caseloads. The technology has been clinically proven to improve cancer detection rates by 8 percent, reduce unnecessary patient recall rates by 7.2 percent, and slash radiologists’ reading time by 52.7 percent and up to 57.4 percent for dense breast 3-D image analysis.

For more information: www.icadmed.com

Related Content

The impact of deploying artificial intelligence (AI) for radiation cancer therapy in a real-world clinical setting has been tested by Princess Margaret researchers in a unique study involving physicians and their patients.

Getty Images

News | Artificial Intelligence | June 15, 2021
June 15, 2021 — The impact of deploying ...
The prevalence of genetic mutations associated with breast cancer in Black and white women is the same, according to a new JAMA Oncology study of nearly 30,000 patients led by researchers in the Basser Center for BRCA at the Abramson Cancer Center.

Getty Images

News | Women's Health | June 15, 2021
June 15, 2021 — The prevalence of genetic mutations associated with breast cancer in Black and white women is the sam
Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

Prediction performance of DL compared to quantitative measures and Kaplan-Meier curves for quartiles of DL. Image created by Singh et al., Cedars-Sinai Medical Center, Los Angeles, CA.

News | SPECT Imaging | June 14, 2021
June 14, 2021 — An advanced artificial i...
Kathryn A. Gold, M.D., associate clinical professor at University of California San Diego School of Medicine, presented data showing an increase in people diagnosed with advanced stage breast cancer in 2020 and 2021, compared to 2019.

Kathryn A. Gold, M.D., associate clinical professor at University of California San Diego School of Medicine, presented data showing an increase in people diagnosed with advanced stage breast cancer in 2020 and 2021, compared to 2019.

News | Breast Imaging | June 08, 2021
June 8, 2021 — Reporting at the 2021 annual meeting of the American S...
Cina Chest is part of Avicenna’s CINA family of AI tools that support the treatment of emergencies, including CINA HEAD, its FDA-cleared and CE-Marked solution that supports the detection and triage of stroke and neurovascular emergencies.
News | Artificial Intelligence | June 03, 2021
June 3, 2021 — Medical imaging AI specialist Avicenna.AI announced
Chest X-rays used in the COVID-Net study show differing infection extent and opacity in the lungs of COVID-19 patients. Image courtesy of University of Waterloo

Chest X-rays used in the COVID-Net study show differing infection extent and opacity in the lungs of COVID-19 patients. Image courtesy of University of Waterloo

News | Coronavirus (COVID-19) | June 03, 2021
June 3, 2021 — Artificial intelligence
International medical imaging IT and cybersecurity company Sectra will install its solution for digital pathology at Institut Curie, one of the most recognized and prestigious cancer centers in France.
News | Enterprise Imaging | May 24, 2021
May 24, 2021 — International medical imaging IT and cybersecurity company ...
Carestream selects HPE GreenLake Cloud Services to power transformative artificial intelligence-as-a-service (AIaas)
News | Artificial Intelligence | May 20, 2021
May 20, 2021 — Carestream Health is transforming and accelerating the way it develops and delivers...